促性腺激素细胞肿瘤的治疗选择:现状与展望
促性腺激素细胞肿瘤约占垂体前叶肿瘤的三分之一,但目前尚无推荐药物治疗。本文通过PubMed检索综述了多巴胺2型受体激动剂、生长抑素受体配体、替莫唑胺、PRRT、免疫治疗、VEGFR靶向治疗、mTOR抑制剂和酪氨酸激酶抑制剂等治疗证据,指出SST2类似物抗肿瘤效果非常有限,高剂量卡麦角林在预防肿瘤再生长方面更有效但仅少数病例有效,侵袭性肿瘤推荐替莫唑胺但疗效也有限,且优于PRRT,其他药物尚无病例报告。
要点
- 促性腺激素细胞肿瘤约占垂体前叶肿瘤的三分之一,目前无推荐药物治疗。
- SST2类似物抗肿瘤效果非常有限,高剂量卡麦角林预防再生长更有效但仅少数病例。
- 侵袭性促性腺激素细胞肿瘤推荐替莫唑胺,但疗效有限,仍优于PRRT。
核心结论
- 促性腺激素细胞肿瘤需要在肿瘤细胞和肿瘤微环境方面进行更好的表型分析以改善治疗。
- 在正式推荐可用之前,作者提供了其建议的促性腺激素细胞肿瘤管理方法,应在多学科团队内讨论。
研究设计与样本
- 综述:2020年3月进行PubMed检索,使用「gonadotroph」结合36个关键词,涉及多巴胺2型受体激动剂、生长抑素受体配体、替莫唑胺、肽受体放射性核素治疗、免疫治疗、VEGFR靶向治疗、mTOR抑制剂和酪氨酸激酶抑制剂。
- 检索所得文章及这些文章引用的相关参考文献被综述。
主要发现
- SST2类似物仅显示出非常有限的抗肿瘤效果。
- 高剂量卡麦角林在预防肿瘤再生长方面更有效,但仅在少数病例中有效。
- 在侵袭性促性腺激素细胞肿瘤中,替莫唑胺是推荐的药物治疗,但疗效也有限。
- 替莫唑胺的疗效迄今为止优于PRRT。
- 文献中未报告促性腺激素细胞肿瘤使用帕瑞肽、VEGFR靶向治疗、mTOR抑制剂、酪氨酸激酶抑制剂或免疫检查点抑制剂治疗的病例。
临床怎么用
- 在正式推荐可用之前,作者提供了其建议的促性腺激素细胞肿瘤管理方法,应在多学科团队内讨论。
局限性
- 文献中未报告促性腺激素细胞肿瘤使用帕瑞肽、VEGFR靶向治疗、mTOR抑制剂、酪氨酸激酶抑制剂或免疫检查点抑制剂治疗的病例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Gonadotroph tumors represent approximatively one-third of anterior pituitary tumors, but despite their frequency, no medical treatment is currently recommended for them. This would be greatly needed because following surgery, which is the first-line treatment, a significant percentage of gonadotroph tumors regrow. EVIDENCE ACQUISITION: We performed PubMed searches in March 2020 using the term "gonadotroph" in combination with 36 different keywords related to dopamine type 2 receptor agonists, somatostatin receptor (SST) ligands, temozolomide, peptide receptor radionuclide therapy (PRRT), immunotherapy, vascular endothelial growth factor receptor (VEGFR)-targeted therapy, mammalian target of rapamycin (mTOR) inhibitors, and tyrosine kinase inhibitors. Articles resulting from these searches, as well as relevant references cited by these articles were reviewed. EVIDENCE SYNTHESIS: SST2 analogs have demonstrated only very limited antitumor effect, while high-dose cabergoline has been more effective in preventing tumor regrowth, but still in only a minority of cases. In the setting of an aggressive gonadotroph tumor, temozolomide is the recommended medical treatment, but has demonstrated also only limited efficacy. Still, its efficacy has been so far better than that of PRRT. No case of a gonadotroph tumor treated with pasireotide, VEGFR-targeted therapy, mTOR inhibitors, tyrosine kinase inhibitors, or immune checkpoint inhibitors is reported in literature. CONCLUSIONS: Gonadotroph tumors need better phenotyping in terms of both tumor cells and associated tumor microenvironment to improve their treatment. Until formal recommendations will be available, we provide the readers with our suggested approach for the management of gonadotroph tumors, management that should be discussed within multidisciplinary teams.
引用
- Ilie MD, Raverot G. Treatment Options for Gonadotroph Tumors: Current State and Perspectives. J Clin Endocrinol Metab. 2020. PMID: 32735647. doi:10.1210/clinem/dgaa497
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。